Clareo Health | Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
40–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Between 40 and 70 years of age.
Confirmed diagnosis of COPD for greater than (\>) 6 months.
Participant is a smoker or an ex-smoker with a smoking history of at least 10 pack years.
A female participant is eligible to participate if she is not pregnant or breastfeeding and agrees to use contraceptives during the study (for women of childbearing potential only).
You may not be if
Participant has poorly controlled or unstable COPD.
Participant has a past or current medical condition(s) or disease(s) that is/are not well controlled.
Participant has had a respiratory tract infection treated with antibiotics within 4 weeks prior to screening.
Participant requires regular treatment with oral corticosteroids or has received a course of oral or parenteral corticosteroids within 4 weeks prior to screening.
Participant requires long-term oxygen therapy.
Current enrolment or past participation in a clinical trial within 30 days before this study starts.
Positive tests for human immunodeficiency virus (HIV), hepatitis B and C, or Coronavirus disease-19 (COVID-19).
Positive pre-study drug (except for as results of opioids prescribed for medical reasons and/or inadvertent consumption of poppy seeds) /alcohol screening result.
